The purpose of this Phase IV study is to determine the effect of secukinumab on total immune
cell numbers obtaines by entheseal biopsy in the inflamed human entheses in patients with
Psoriatic Arthritis. This is a single arm, single centre, prospective, open label study with
secukinumab.